{
  "asset": "ERLEADA (apalutamide)",
  "query_terms": [
    "ERLEADA (apalutamide)",
    "apalutamide",
    "ERLEADA"
  ],
  "returned_unique": 20,
  "kept": 10,
  "studies": [
    {
      "nct_id": "NCT07002320",
      "title": "ASpiRE: A Proof-of-mechanism and Proof-of-concept Clinical Trial Evaluating the Safety, Tolerability, Biological and Anti-tumour Activity of Apalutamide With Dual CXCR1 and CXCR2 Blockade by SX-682 for Men Suffering From Metastatic Castration-resistant Prostate Cancer (mCRPC)",
      "overall_status": "RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Metastatic Castrate-Resistant Prostate Cancer (mCRPC)"
      ],
      "lead_sponsor": "Institute of Cancer Research, United Kingdom",
      "collaborators": [
        "Prostate Cancer UK",
        "Janssen Pharmaceutica N.V., Belgium",
        "Oncology Institute of Southern Switzerland",
        "Syntrix Biosystems, Inc.",
        "Royal Marsden NHS Foundation Trust",
        "Cambridge University Hospitals NHS Foundation Trust",
        "Belfast Health and Social Care Trust",
        "Institute of Oncology Research (IOR)"
      ],
      "interventions": [
        "SX-682",
        "Apalutamide"
      ],
      "last_update": "2025-12-04",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT07002320"
    },
    {
      "nct_id": "NCT03767244",
      "title": "A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Apalutamide",
        "Androgen Deprivation Therapy (ADT)",
        "Placebo"
      ],
      "last_update": "2025-12-05",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT03767244"
    },
    {
      "nct_id": "NCT04523207",
      "title": "A Multi-center, Open-label, Single-arm Phase 2 Study of the Adjuvant Treatment of Apalutamide and Androgen Deprivation Therapy (ADT) in Treatment-na√Øve Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases",
      "overall_status": "COMPLETED",
      "phase": "Phase 2",
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Apalutamide",
        "ADT",
        "Relugolix"
      ],
      "last_update": "2025-04-25",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04523207"
    },
    {
      "nct_id": "NCT03802682",
      "title": "A Randomized, Open-label, Two-way, Crossover Study to Evaluate the Relative Bioavailability of Apalutamide Administered Orally as Whole Tablets and as a Mixture in Applesauce in Healthy Subjects",
      "overall_status": "COMPLETED",
      "phase": "Phase 1",
      "conditions": [
        "Healthy"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Apalutamide"
      ],
      "last_update": "2025-02-03",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT03802682"
    },
    {
      "nct_id": "NCT04181203",
      "title": "An Open Label, Randomized, Phase III Study, Evaluating the Efficacy of a Combination of Apalutamide With Radiotherapy and LHRH Agonist in High-risk Postprostatectomy Biochemically Relapsed Prostate Cancer Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Prostate Cancer"
      ],
      "lead_sponsor": "UNICANCER",
      "collaborators": [
        "Janssen Pharmaceutica"
      ],
      "interventions": [
        "Apalutamide",
        "Salvage radiotherapy (SRT)",
        "Luteinising Hormone Releasing Hormone agonist (LHRHa)"
      ],
      "last_update": "2025-07-30",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04181203"
    },
    {
      "nct_id": "NCT03903835",
      "title": "ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metastatic Prostate Cancer",
      "overall_status": "RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Metastatic Castration-resistant Prostate Cancer (mCRPC)",
        "Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"
      ],
      "lead_sponsor": "Karolinska Institutet",
      "collaborators": [
        "The Swedish Research Council",
        "Kom Op Tegen Kanker",
        "Janssen Pharmaceutica N.V., Belgium",
        "AstraZeneca",
        "Cancerfonden"
      ],
      "interventions": [
        "Enzalutamide Oral Capsule",
        "Abiraterone Oral Tablet",
        "Carboplatin",
        "Cabazitaxel 60 mg Solution for Injection",
        "Docetaxel Injectable Solution",
        "Radium Chloride Ra-223",
        "Niraparib plus Abiraterone acetate plus Prednisone",
        "Capivasertib plus Docetaxel",
        "Apalutamide",
        "Darolutamide"
      ],
      "last_update": "2025-04-09",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT03903835"
    },
    {
      "nct_id": "NCT05683964",
      "title": "Understanding the Interaction Between Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression",
      "overall_status": "RECRUITING",
      "phase": null,
      "conditions": [
        "Prostate Adenocarcinoma",
        "Prostate Cancer",
        "Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"
      ],
      "lead_sponsor": "Beth Israel Deaconess Medical Center",
      "collaborators": [
        "Dana-Farber Cancer Institute"
      ],
      "interventions": [
        "Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]",
        "Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan"
      ],
      "last_update": "2024-08-16",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT05683964"
    },
    {
      "nct_id": "NCT02903368",
      "title": "Phase II Randomized Study Of Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide For Intermediate-High Risk Prostate Cancer Undergoing Prostatectomy",
      "overall_status": "COMPLETED",
      "phase": "Phase 2",
      "conditions": [
        "Prostate Cancer"
      ],
      "lead_sponsor": "Dana-Farber Cancer Institute",
      "collaborators": [
        "Janssen Scientific Affairs, LLC"
      ],
      "interventions": [
        "Apalutamide",
        "Leuprolide",
        "Prednisone",
        "Abiraterone Acetate"
      ],
      "last_update": "2025-06-13",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT02903368"
    },
    {
      "nct_id": "NCT02531516",
      "title": "ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Prostatic Neoplasms"
      ],
      "lead_sponsor": "Aragon Pharmaceuticals, Inc.",
      "collaborators": [],
      "interventions": [
        "Apalutamide",
        "Bicalutamide",
        "Bicalutamide Placebo",
        "Apalutamide Placebo",
        "GnRH (agonist)",
        "74-80 Grays (units of radiation)"
      ],
      "last_update": "2025-12-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT02531516"
    },
    {
      "nct_id": "NCT03569280",
      "title": "A First-in-Human Study to Determine the Safety, Pharmacokinetics and Efficacy of KPG-121 When Administered With Enzalutamide, Abiraterone, or Apalutamide in Subjects With Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer",
      "overall_status": "COMPLETED",
      "phase": "Phase 1",
      "conditions": [
        "Castration-Resistant Prostate Cancer"
      ],
      "lead_sponsor": "Kangpu Biopharmaceuticals, Ltd.",
      "collaborators": [],
      "interventions": [
        "Enzalutamide or Abiraterone or Apalutamid"
      ],
      "last_update": "2023-07-18",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT03569280"
    }
  ]
}